The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells
Open accessAbstract
Glioblastoma multiforme (GBM), the most aggressive brain cancer, recurs because glioblastoma stem cells (GSCs) are resistant to all standard therapies. We showed that GSCs, but not normal astrocytes, are sensitive to lysis by healthy allogeneic natural killer (NK) cells in vitro. Mass cytometry and single-cell RNA sequencing of primary tumor samples revealed that GBM tumor-infiltrating NK cells acquired an altered phenotype associated with impaired lytic function relative to matched peripheral blood NK cells from patients with GBM or healthy donors. We attributed this immune evasion tactic to direct cell-to-cell contact between GSCs and NK cells via αv integrin-mediated TGF-β activation. Treatment of GSC-engrafted mice with allogeneic NK cells in combination with inhibitors of integrin or TGF-β signaling or with TGFBR2 gene-edited allogeneic NK cells prevented GSC-induced NK cell dysfunction and tumor growth. These findings reveal an important mechanism of NK cell immune evasion by GSCs and suggest the αv integrin/TGF-β axis as a potentially useful therapeutic target in GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151 · cited 8×
“The αv integrins have been proposed to modulate latent TGF-β activation through two different mechanisms: (i) an MMP-dependent mechanism based on the production of MMP2 and MMP9 by glioma cells and GSCs, but not healthy brain tissue(33), leading to proteolytic cleavage TGF-β from LAP and (ii), an MMP-independent mecha…”
BackgroundInfluentialRoles of matrix metalloproteinases in cancer progression and their pharmacological targeting
Gialeli, C., Theocharis, A. D., & Karamanos, N. K. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07919.x · Cited by 1,607
Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052 · cited 1×
“In addition, the negative clinical data with cilengitide in GBM (54) may be at least partly explained by our observation that TGF-β inhibition prevents, but does not reverse, the state of established NK cell dysfunction induced by TGF-β in the tumor microenvironment.”
BackgroundPollard, S. M., Yoshikawa, K., Clarke, I. D., Danovi, D., Stricker, S., Russell, R., Bayani, J., Head, R., Lee, M., Bernstein, M., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.03.014 · Cited by 1,025
Darmanis, S., Sloan, S. A., Croote, D., Mignardi, M., Chernikova, S., Samghababi, P., Zhang, Y., Neff, N., Kowarsky, M., Caneda, C., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.030 · Cited by 997
Self-citationTGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
Viel, S., Marçais, A., Guimaraes, F. S.-F., Loftus, R., Rabilloud, J., Grau, M., Degouve, S., Djebali, S., Sanlaville, A., Charrier, E., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aad1884 · Cited by 672
Cerwenka, A., Baron, J. L., & Lanier, L. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201238598 · Cited by 606
Lahn, M., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A. L., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 554
Immune microenvironment of gliomas
Gieryng, A., Pszczolkowska, D., Walentynowicz, K. A., Rajan, W. D., & Kaminska, B. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.19 · Cited by 538
Integrins and the activation of latent transforming growth factor β1 – An intimate relationship
Wipff, P.-J., & Hinz, B. (2008) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2008.01.012 · Cited by 517
Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq142 · Cited by 433
Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy
Lan, X., Jörg, D. J., Cavalli, F. M. G., Richards, L. M., Nguyen, L. V., Vanner, R. J., Guilhamon, P., Lee, L., Kushida, M. M., Pellacani, D., et al. (2017) · Nature · doi:10.1038/nature23666 · Cited by 405
Kmiecik, J., Poli, A., Brons, N. H. C., Waha, A., Eide, G. E., Enger, P. Ø., Zimmer, J., & Chekenya, M. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.08.013 · Cited by 389
Deryugina, E. I., Ratnikov, B., Monosov, E., Postnova, T. I., DiScipio, R., Smith, J. W., & Strongin, A. Y. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5118 · Cited by 387
‘Yin–Yang’ functions of transforming growth factor‐β and T regulatory cells in immune regulation
Wan, Y. Y., & Flavell, R. A. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00565.x · Cited by 380
Immunosuppressive mechanisms in glioblastoma: Fig. 1.
Nduom, E. K., Weller, M., & Heimberger, A. B. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov151 · Cited by 348
Self-citationGabrusiewicz, K., Li, X., Wei, J., Hashimoto, Y., Marisetty, A. L., Ott, M., Wang, F., Hawke, D., Yu, J., Healy, L. M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1412909 · Cited by 348
Self-citationNK Cells Recognize and Kill Human Glioblastoma Cells with Stem Cell-Like Properties
Castriconi, R., Daga, A., Dondero, A., Zona, G., Poliani, P. L., Melotti, A., Griffero, F., Marubbi, D., Spaziante, R., Bellora, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802845 · Cited by 337
NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma
Weiss, T., Weller, M., Guckenberger, M., Sentman, C. L., & Roth, P. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1788 · Cited by 287
Jiang, H., Gomez-Manzano, C., Aoki, H., Alonso, M. M., Kondo, S., McCormick, F., Xu, J., Kondo, Y., Bekele, B. N., Colman, H., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm102 · Cited by 278
Self-citationBrandes, A. A., Carpentier, A. F., Kesari, S., Sepulveda-Sanchez, J. M., Wheeler, H. R., Chinot, O., Cher, L., Steinbach, J. P., Capper, D., Specenier, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now009 · Cited by 273
Lottaz, C., Beier, D., Meyer, K., Kumar, P., Hermann, A., Schwarz, J., Junker, M., Oefner, P. J., Bogdahn, U., Wischhusen, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1707 · Cited by 272
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
Rezvani, K., & Rouce, R. H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00578 · Cited by 272
Self-citationZhang, M., Kleber, S., Röhrich, M., Timke, C., Han, N., Tuettenberg, J., Martin-Villalba, A., Debus, J., Peschke, P., Wirkner, U., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1212 · Cited by 249
An implantable guide-screw system for brain tumor studies in small animals
Lal, S., Lacroix, M., Tofilon, P., Fuller, G. N., Sawaya, R., & Lang, F. F. (2000) · Journal of Neurosurgery · doi:10.3171/jns.2000.92.2.0326 · Cited by 244
Self-citationNext generation natural killer cells for cancer immunotherapy: the promise of genetic engineering
Daher, M., & Rezvani, K. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.013 · Cited by 224
Self-citationKim, E.-S., Kim, M.-S., & Moon, A. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.5.1375 · Cited by 219
The expression of matrix metalloproteinase-2 and-9 in human gliomas of different pathological grades
Wang, M., Wang, T., Liu, S., Yoshida, D., & Teramoto, A. (2003) · Brain Tumor Pathology · doi:10.1007/bf02483449 · Cited by 219
TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
Dahmani, A., & Delisle, J.-S. (2018) · Cancers · doi:10.3390/cancers10060194 · Cited by 214
Shah, N., Martin-Antonio, B., Yang, H., Ku, S., Lee, D. A., Cooper, L. J. N., Decker, W. K., Li, S., Robinson, S. N., Sekine, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076781 · Cited by 199
Self-citationaV integrins and TGF‐β‐induced EMT: a circle of regulation
Mamuya, F. A., & Duncan, M. K. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01419.x · Cited by 185
Hsieh, H.-L., Wang, H.-H., Wu, W.-B., Chu, P.-J., & Yang, C.-M. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-88 · Cited by 183
Liu, Z., Kuang, W., Zhou, Q., & Zhang, Y. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3923 · Cited by 148
Integrin control of the transforming growth factor-β pathway in glioblastoma
Roth, P., Silginer, M., Goodman, S. L., Hasenbach, K., Thies, S., Maurer, G., Schraml, P., Tabatabai, G., Moch, H., Tritschler, I., et al. (2013) · Brain · doi:10.1093/brain/aws351 · Cited by 120
Boutet, M., Gauthier, L., Leclerc, M., Gros, G., de Montpréville, V., Théret, N., Donnadieu, E., & Mami‐Chouaib, F. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1545 · Cited by 111
Transforming growth factor-β pathway activity in glioblastoma
Frei, K., Gramatzki, D., Tritschler, I., Schroeder, J. J., Espinoza, L., Rushing, E. J., & Weller, M. (2015) · Oncotarget · doi:10.18632/oncotarget.3467 · Cited by 104
Metabolic heterogeneity and plasticity of glioma stem cells in a mouse glioblastoma model
Shibao, S., Minami, N., Koike, N., Fukui, N., Yoshida, K., Saya, H., & Sampetrean, O. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox170 · Cited by 102
Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment
Gonzàlez-Juncà, A., Driscoll, K. E., Pellicciotta, I., Du, S., Lo, C. H., Roy, R., Parry, R., Tenvooren, I., Marquez, D. M., Spitzer, M. H., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0310 · Cited by 97
Thomas, G. J., Poomsawat, S., Lewis, M. P., Hart, I. R., Speight, P. M., & Marshall, J. F. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2001.01352.x · Cited by 96
A gene expression-based study on immune cell subtypes and glioma prognosis
Zhong, Q.-Y., Fan, E., Feng, G., Chen, Q., Gou, X., Yue, G., & Zhang, G.-H. (2019) · BMC Cancer · doi:10.1186/s12885-019-6324-7 · Cited by 81
Close, H. J., Stead, L. F., Nsengimana, J., Reilly, K., Droop, A., Wurdak, H., Mathew, R. K., Corns, R. A., Newton‐Bishop, J., Melcher, A. A., et al. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13403 · Cited by 77
Thang, N. N. T., Derouazi, M., Philippin, G., Arcidiaco, S., Berardino-Besson, W. D., Masson, F., Hoepner, S., Riccadonna, C., Burkhardt, K., Guha, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3074 · Cited by 70
Activating Signals Dominate Inhibitory Signals in CD137L/IL-15 Activated Natural Killer Cells
Zhang, H., Cui, Y., Voong, N., Sabatino, M., Stroncek, D. F., Morisot, S., Civin, C. I., Wayne, A. S., Levine, B. L., & Mackall, C. L. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31820d2a21 · Cited by 49
Integrin αvβ6-associated ERK2 mediates MMP-9 secretion in colon cancer cells
Gu, X., Niu, J., Dorahy, D. J., Scott, R. J., & Agrez, M. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600480 · Cited by 45
Roy, L.-O., Poirier, M.-B., & Fortin, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041113 · Cited by 45
Tanaka, Y., Nakazawa, T., Nakamura, M., Nishimura, F., Matsuda, R., Omoto, K., Shida, Y., Murakami, T., Nakagawa, I., Motoyama, Y., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212455 · Cited by 45
General structural features that regulate integrin affinity revealed by atypical αVβ8
Wang, J., Su, Y., Iacob, R. E., Engen, J. R., & Springer, T. A. (2019) · Nature Communications · doi:10.1038/s41467-019-13248-5 · Cited by 37
A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation
Li, L., Chen, H., Marín, D., Xi, Y., Miao, Q., Lv, J., Banerjee, P. P., Shaim, H., Daher, M., Başar, R., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000835 · Cited by 37
Self-citationImmunological characterization of glioblastoma cells for immunotherapy.
Jung, T., Choi, Y. D., Kim, Y., Lee, J., Kim, H.-S., Kim, J.-S., Kim, S., Jung, S., & Cho, D. (2013) · PubMed · Cited by 35
The CD9, CD81, and CD151 EC2 domains bind to the classical RGD-binding site of integrin αvβ3
Yu, F., Lee, C.-Y., Changou, C. A., Cedano-Prieto, D. M., Takada, Y. K., & Takada, Y. (2016) · Biochemical Journal · doi:10.1042/bcj20160998 · Cited by 32
Capper, D., von Deimling, A., Brandes, A. A., Carpentier, A., Kesari, S., Sepúlveda-Sánchez, J. M., Wheeler, H., Chinot, O. L., Cher, L., Steinbach, J. P., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050995 · Cited by 30
Tada, T., Yabu, K., & Kobayashi, S. (1993) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1993.tb00174.x · Cited by 29
αvβ6 integrin is required for TGFβ1-mediated matrix metalloproteinase2 expression
Dutta, A., Li, J., Fedele, C., Sayeed, A., Singh, A., Violette, S. M., Manes, T. D., & Languino, L. R. (2015) · Biochemical Journal · doi:10.1042/bj20140698 · Cited by 28
Pathological features of highly invasive glioma stem cells in a mouse xenograft model
Sadahiro, H., Yoshikawa, K., Ideguchi, M., Kajiwara, K., Ishii, A., Ikeda, E., Owada, Y., Yasumoto, Y., & Suzuki, M. (2013) · Brain Tumor Pathology · doi:10.1007/s10014-013-0149-x · Cited by 25
Cited by
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
Self-citationCAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 658
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01207-0 · Cited by 373
Tumor microenvironment in glioblastoma: Current and emerging concepts
Sharma, P., Aaroe, A., Liang, J., & Puduvalli, V. K. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad009 · Cited by 314
Natural killer cell homing and trafficking in tissues and tumors: from biology to application
Ran, G. H., Lin, Y. Q., Tian, L., Zhang, T., Yan, D. M., Yu, J. H., & Deng, Y. C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01058-z · Cited by 282
Self-citation
Metadata
- Authors
- Shaim, H., Shanley, M., Basar, R., Daher, M., Gumin, J., Zamler, D. B., Uprety, N., Wang, F., Huang, Y., Gabrusiewicz, K., Miao, Q., Dou, J., Alsuliman, A., Kerbauy, L. N., Acharya, S., Mohanty, V., Mendt, M., Li, S., Lu, J., Wei, J., Fowlkes, N. W., Gokdemir, E., Ensley, E. L., Kaplan, M., Kassab, C., Li, L., Ozcan, G., Banerjee, P. P., Shen, Y., Gilbert, A. L., Jones, C. M., Bdiwi, M., Nunez-Cortes, A. K., Liu, E., Yu, J., Imahashi, N., Muniz-Feliciano, L., Li, Y., Hu, J., Draetta, G., Marin, D., Yu, D., Mielke, S., Eyrich, M., Champlin, R. E., Chen, K., Lang, F. F., Shpall, E. J., Heimberger, A. B., & Rezvani, K.
- Venue
- Journal of Clinical Investigation
- Published
- 2021-07-15
- Volume
- 131
- Issue
- 14
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3171571522
- Cited by
- 263
- References
- 56
- FWCI
- 12.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.